Antibodies
20 September 2024
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™20 September 2024
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX4519 September 2024
Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 202418 September 2024
GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers18 September 2024
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 202418 September 2024
Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.18 September 2024
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 202416 September 2024
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 202416 September 2024
Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer PatientsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports